{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-089684","form_type":"8-K","ticker":"XWEL","cik":"0001410428","company_name":"XWELL, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.954630+00:00","generated_at":"2026-05-31T09:17:12.971961+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"XWELL Q2 2024 revenue up 14% to $9.3M; net loss narrows to $2.0M from $5.7M","bullets":["Revenue $9.3M (vs $8.2M Q2 2023); operating loss improved to $1.9M from $4.7M.","Net loss attributable to XWELL was $2.0M, down from $5.7M in prior year quarter.","Opened new XpresSpa at Philadelphia airport; plans NYC Penn Station later 2024.","CDC issued new 3-year biosurveillance RFP; XpresTest bidding; contract value similar to prior.","Closed $1.4M registered direct offering at $2.18/share; cash & marketable securities $18.4M, no debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-089684","json":"https://secwatch.observer/filing/0001104659-24-089684.json","markdown":"https://secwatch.observer/filing/0001104659-24-089684.md","text":"https://secwatch.observer/filing/0001104659-24-089684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1410428/000110465924089684/0001104659-24-089684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1410428/000110465924089684/tm2421605d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:17:12.971961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}